ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

Rhea-AI Summary

ArriVent (Nasdaq: AVBP) announced FDA IND clearance for ARR-002, a tetravalent MUC16/NaPi2b-targeting antibody-drug conjugate with initial focus in ovarian and endometrial cancers. The company reported preclinical data showing enhanced dual-target binding, improved internalization, superior in vivo efficacy in OVCAR-3 xenografts, and a favorable tolerability profile in cynomolgus monkeys. ArriVent expects to begin a Phase 1 trial and dose the first patient in the second half of 2026.

Positive

• FDA IND clearance for ARR-002 enabling human clinical testing
• Phase 1 initiation expected in the second half of 2026
• Preclinical: superior in vivo efficacy in OVCAR-3 xenograft model
• Favorable tolerability in cynomolgus monkeys with reversible findings

Negative

• No clinical human safety or efficacy data reported yet
• Phase 1 timing stated as expectation, not a firm start date

News Market Reaction – AVBP

-2.60%

-2.60% Session close to close

In the May 7 session, AVBP declined 2.60%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement advances ArriVent’s ADC strategy, with FDA IND clearance for ARR-002 and a Phase 1...

Analysis

This announcement advances ArriVent’s ADC strategy, with FDA IND clearance for ARR-002 and a Phase 1 trial planned for the second half of 2026 in ovarian and endometrial cancers. It follows prior AACR preclinical data and complements the company’s firmonertinib Phase 3 programs. Investors may watch for detailed Phase 1 design, early safety and efficacy signals, and how ARR-002 integrates with ArriVent’s broader solid tumor portfolio.

Key Figures

Phase 1 initiation timing: Second half of 2026

1 metrics

Phase 1 initiation timing Second half of 2026 Planned start of first-in-human trial for ARR-002

Historical Context

5 past events · Latest: Mar 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 17	AACR poster plans	Positive	-5.0%	Announced AACR posters for firmonertinib and ARR-002 with supportive preclinical data.
Mar 17	AACR ADC showcase	Positive	-5.0%	Detailed upcoming AACR presentations on AV-P138-ADC (ARR-002) and ADC platform innovations.
Mar 05	Full-year 2025 results	Neutral	-7.2%	Reported 2025 financials with higher R&D, larger net loss, and cash runway into 3Q 2027.
Dec 22	Phase 3 first dosing	Positive	+1.8%	First patient dosed in pivotal Phase 3 ALPACCA trial for firmonertinib in EGFR PACC NSCLC.
Nov 10	Q3 2025 results	Positive	+3.1%	Reported Q3 2025 results with IND clearance for ARR-217 and plans for pivotal ALPACCA enrollment.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent AVBP news often skews positive clinically, but price reactions have been mixed, with some clinically positive updates drawing negative or muted trading responses.

Recent Company History

Over the past several months, ArriVent has advanced both its EGFR franchise and ADC pipeline. Key milestones include Phase 3 progress for firmonertinib, IND clearance and early clinical work for ARR-217, and multiple AACR 2026 presentations highlighting firmonertinib and ARR-002. Financial updates in 2025 detailed rising R&D and larger net losses alongside solid cash balances. Today’s IND clearance for ARR-002 continues the shift from preclinical AACR data toward first-in-human development in ovarian and endometrial cancers.

Key Terms

investigational new drug (ind), muc16, napi2b, antibody-drug conjugate, +4 more

8 terms

investigational new drug (ind) regulatory

"announced clearance of an investigational new drug (IND) application"

An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing — like getting a permit to run real-world experiments — which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company's value.

muc16 medical

"a potential first-in-class MUC16/NaPi2b targeting tetravalent antibody-drug conjugate"

MUC16 is a gene that makes a very large, sticky cell-surface protein commonly measured in medicine as the blood marker CA‑125; that protein helps form protective coatings on cells and is often shed into the bloodstream by certain tumors. Investors watch it because changes in its blood levels are used to detect and monitor some cancers and because the protein itself is a direct target for diagnostics and drug development—like a visible flag on diseased cells that companies can measure or aim at.

napi2b medical

"a potential first-in-class MUC16/NaPi2b targeting tetravalent antibody-drug conjugate"

NaPi2b is a protein on the surface of some cells that helps transport phosphate into the cell. In many cancers it is produced at higher levels, acting like an address label that distinguishes tumor cells from normal ones, so drugs or diagnostic tests that recognize NaPi2b can deliver treatment more directly or identify patients likely to benefit. For investors, programs targeting NaPi2b can meaningfully affect a biotech’s clinical prospects, market value and risk profile.

antibody-drug conjugate medical

"tetravalent antibody-drug conjugate (ADC) with an initial focus in ovarian"

An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.

adc medical

"tetravalent antibody-drug conjugate (ADC) with an initial focus in ovarian"

An antibody-drug conjugate (ADC) is a targeted cancer medicine that pairs an antibody that recognizes specific markers on tumor cells with a potent cell-killing drug, connected so the toxic payload is delivered directly to the cancer. For investors, ADCs matter because successful ADCs can improve patient outcomes and reduce side effects compared with traditional chemotherapy, shaping clinical trial success, regulatory approval chances, commercial demand, and a company’s valuation much like a guided missile versus a general bomb.

xenograft model medical

"Superior in vivo efficacy vs. single-target ADCs in the OVCAR-3 xenograft model"

A xenograft model is an experimental setup in which human cells or tissues, often tumors, are implanted into an animal (commonly a mouse) to study disease behavior and test treatments in a living system. For investors, results from xenograft studies can indicate whether a drug or therapy has the potential to work in humans and help de-risk early-stage programs, but they are an imperfect stand-in—like testing a prototype on a crash-test dummy rather than in full real-world conditions.

cynomolgus monkeys medical

"favorable tolerability profile in cynomolgus monkeys, consisting of reversible"

A species of macaque commonly used in early-stage safety and effectiveness studies for drugs, vaccines and medical devices because their biology is similar to humans. Think of them as a biological stand-in used to check whether a treatment is likely safe or works before it is tested in people; results from these studies can affect development timelines, regulatory reviews, costs and the investment risk of a potential therapy.

therapeutic window medical

"The potential for a wider therapeutic window based on a favorable tolerability profile"

The "therapeutic window" is the optimal range of a medication's dosage where it effectively treats a condition without causing harmful side effects. For investors, understanding this concept highlights the importance of balance—just as too little medication may be ineffective and too much can be dangerous, financial strategies or investments need to be carefully managed within safe limits to achieve desired results without undue risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approaches
• Phase 1 initiation expected in the second half of 2026

NEWTOWN SQUARE, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ARR-002, a potential first-in-class MUC16/NaPi2b targeting tetravalent antibody-drug conjugate (ADC) with an initial focus in ovarian and endometrial cancers and broader therapeutic potential across solid tumors.

“We are pleased to advance ARR-002 into the clinic as the second next-generation ADC from our portfolio,” said Stuart Lutzker, MD, Ph.D., President of Research and Development of ArriVent. “At AACR, compelling preclinical data was presented demonstrating ARR-002’s potential to improve safety and efficacy over conventional single-target and bivalent bispecific ADCs in ovarian and endometrial cancers. ARR-002’s dual-target approach is designed to improve delivery and reduce off-tumor toxicity to overcome key limitations of single-target ADCs, including limited internalization, suboptimal payload delivery, and heterogeneous target expression. We expect to initiate a Phase 1 trial and dose the first patient in the second half of the year.”

MUC16 and NaPi2b are highly expressed on ovarian and endometrial cancers with limited expression in normal tissues, making them strong co-targets. Select preclinical data included in the IND submission of ARR-002 was presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting in a joint presentation with Aarvik Therapeutics demonstrating:

• Effective binding to individual targets, simultaneous engagement of both targets, and enhanced internalization vs. single-target antibody controls
• Superior in vivo efficacy vs. single-target ADCs in the OVCAR-3 xenograft model
• The potential for a wider therapeutic window based on a favorable tolerability profile in cynomolgus monkeys, consisting of reversible hematologic findings at a higher maximum tolerated single dose vs. other approaches in development
  
  

About ArriVent
ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.

About ARR-002

ARR-002 (also known as AV-P138-ADC) is a first-in-class, Mucin-16 (MUC16) and sodium-dependent phosphate transport protein 2b (NaPi2b) dual-target, tetravalent (2+2 format) ADC, with site-specific conjugation to vcMMAE at a drug-to-antibody ratio (DAR) of 4. Both these cell surface antigens are expressed in ovarian and endometrial cancers with limited expression in normal tissues, making them strong co-targets.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, estimates of our addressable market, activity and safety of ARR-002 compared to available therapies, anticipated clinical milestones, including the timing of, and results of global development of ARR-002 including initiating a Phase 1 trial and dosing the first patient, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on ArriVent’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 5, 2026 and our other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ArriVent undertakes no duty to update such information except as required under applicable law.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

FAQ

What does ArriVent's IND clearance for ARR-002 (AVBP) mean for investors?

IND clearance allows ArriVent to begin clinical testing of ARR-002 in humans. According to the company, the FDA cleared the IND, enabling a Phase 1 trial planned for the second half of 2026 to evaluate safety and dosing in ovarian and endometrial cancers.

When will ArriVent (AVBP) start dosing patients in the ARR-002 Phase 1 trial?

ArriVent expects to dose the first patient in the second half of 2026. According to the company, Phase 1 initiation is planned for that timeframe but is described as an expectation rather than a guaranteed start date.

What preclinical results supported ARR-002's IND clearance for AVBP?

Preclinical data showed dual-target binding, enhanced internalization, and superior efficacy in OVCAR-3 xenografts. According to the company, additional IND data reported favorable tolerability in cynomolgus monkeys with reversible hematologic findings.

Which cancers is ARR-002 (AVBP) initially targeting and why?

ARR-002 is initially focused on ovarian and endometrial cancers due to high MUC16 and NaPi2b expression. According to the company, those targets have limited normal-tissue expression, supporting a dual-target ADC approach to improve delivery and reduce off-tumor toxicity.

Does the ARR-002 IND clearance guarantee clinical success for ArriVent (AVBP)?

No, IND clearance permits human trials but does not guarantee success. According to the company, ARR-002 demonstrated promising preclinical results, but clinical safety, dosing, and efficacy will require Phase 1 and subsequent trial data to establish benefit.